Sensei Biotherapeutics to Present at Upcoming Conferences

Rhea-AI Summary

Sensei Biotherapeutics, Inc. (SNSE) will be presenting at Oppenheimer's 34th Annual Healthcare Life Sciences Conference and the 10th Annual Immuno-Oncology 360 Conference in February 2024. The company's management will present virtually at the Oppenheimer conference and in person at the IO360 conference in Brooklyn, NY. A webcast of the Oppenheimer presentation will be available on the Sensei website, with a replay available for 90 days after the event.

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in February 2024:

Oppenheimer’s 34^th Annual Healthcare Life Sciences Conference
Wednesday, February 14, 2024, at 10:00 a.m. ET.
Virtual

10^th Annual Immuno-Oncology 360 Conference (IO360)
Thursday, February 29, 2024, at 11:10 a.m. ET
Brooklyn, NY

A webcast of Sensei’s presentation at Oppenheimer will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the webcast is available here. 

About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn. 

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com

FAQ

When will Sensei Biotherapeutics, Inc. (SNSE) present at Oppenheimer's conference?

Sensei Biotherapeutics, Inc. (SNSE) will present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 10:00 a.m. ET.

Where will Sensei Biotherapeutics, Inc. (SNSE) present at the IO360 conference?

Sensei Biotherapeutics, Inc. (SNSE) will present at the 10th Annual Immuno-Oncology 360 Conference (IO360) in Brooklyn, NY, on Thursday, February 29, 2024, at 11:10 a.m. ET.

Will the presentation at Oppenheimer's conference be available for viewing online?

Yes, a webcast of Sensei Biotherapeutics, Inc.'s (SNSE) presentation at Oppenheimer's conference will be available in the Investors section of the Sensei website.

How long will the webcast replay be available after the Oppenheimer conference?

The webcast replay will be available on the Sensei website for approximately 90 days following the Oppenheimer conference.